Table 4.
All (n=308)* | Non-black (n=115)** | Black (n=193)** | |||||||
---|---|---|---|---|---|---|---|---|---|
n | OR | 95% CI | n | OR | 95% CI | n | OR | 95% CI | |
BMI (kg/m2) | |||||||||
Normal | 64 | 1.00 | Ref | 24 | 1.00 | Ref | 40 | 1.00 | Ref |
Overweight | 110 | 0.90 | 0.43–1.89 | 44 | 1.08 | 0.32–3.62 | 66 | 0.84 | 0.32–2.21 |
Obese | 73 | 1.03 | 0.45–2.34 | 23 | 1.43 | 0.34–6.06 | 50 | 0.96 | 0.34–2.68 |
Severely obese | 61 | 2.97 | 1.21–7.26 | 24 | 2.54 | 0.59–10.91 | 37 | 3.71 | 1.14–12.1 |
p-trend | 0.054 | 0.119 | 0.170 | ||||||
| |||||||||
WC (cm) | |||||||||
T1 (≤100) | 102 | 1.00 | Ref | 33 | 1.00 | Ref | 69 | 1.00 | Ref |
T2 (101–111) | 103 | 1.27 | 0.66–2.46 | 42 | 1.12 | 0.36–3.48 | 61 | 1.29 | 0.55–2.95 |
T3 (≥112) | 103 | 2.00 | 1.02–3.92 | 40 | 1.54 | 0.48–4.92 | 63 | 2.45 | 1.04–5.77 |
p-trend | 0.040 | 0.446 | 0.040 | ||||||
| |||||||||
SFA (cm2) | |||||||||
T1 (≤236) | 102 | 1.00 | Ref | 39 | 1.00 | Ref | 63 | 1.00 | Ref |
T2 (237–353) | 103 | 1.35 | 0.70–2.60 | 47 | 1.12 | 0.39–3.24 | 56 | 1.52 | 0.64–3.62 |
T3 (≥354) | 103 | 2.35 | 1.19–4.65 | 29 | 4.08 | 1.05–15.91 | 74 | 2.07 | 0.91–4.71 |
p-trend | 0.025 | 0.048 | 0.093 | ||||||
| |||||||||
VFA (cm2) | |||||||||
T1 (≤168) | 102 | 1.00 | Ref | 23 | 1.00 | Ref | 79 | 1.00 | Ref |
T2 (169–263) | 103 | 1.16 | 0.59–2.24 | 41 | 0.46 | 0.12–1.78 | 62 | 1.30 | 0.57–2.94 |
T3 (≥264) | 103 | 2.12 | 1.07–4.22 | 51 | 0.64 | 0.18–2.24 | 52 | 4.23 | 1.67–10.69 |
p-trend | 0.024 | 0.831 | 0.002 | ||||||
| |||||||||
PPAT area (cm2) | |||||||||
T1 (≤32) | 102 | 1.00 | Ref | 23 | 1.00 | Ref | 79 | 1.00 | Ref |
T2 (33–43) | 103 | 1.05 | 0.55–2.00 | 42 | 0.24 | 0.06–0.98 | 62 | 1.61 | 0.72–3.59 |
T3 (≥44) | 103 | 1.39 | 0.70–2.76 | 50 | 0.37 | 0.08–1.60 | 52 | 1.88 | 0.80–4.44 |
p-trend | 0.342 | 0.539 | 0.135 |
BMI=body mass index; PPAT=periprostatic adipose tissue; Ref=reference group; SFA=subcutaneous fat area; T=tertile; VFA=visceral fat area; WC=waist circumference
Biopsy Gleason ≥7 versus <7
Adjusted for age, race, PSA, clinical stage, duration of ADT, year of radiation
Adjusted for age, PSA, clinical stage, duration of ADT, year of radiation